drugset / Trial / NCT05533788

ABSK091 Food Effect Study in Healthy Subjects

NCT05533788

Phase 1 Completed 13 enrolled Abbisko Therapeutics Co, Ltd
RandomizedCrossoverDouble-blindOther

Summary

In this study, a single oral dose of the tablet formulation administered under fed conditions will be compared to administration under fasted conditions to assess the effects of a high-fat meal on the rate and extent of absorption and exposure. Study ABSK091-101 is a single-center, Phase 1, open-label, randomized, two-period, two-sequence, and crossover study in healthy subjects.

Timeline

Start
2020-09-08
Primary completion
2021-04-30
Completion
2021-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexagratinib Small molecule Oral

Indications

No indication recorded.